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 
Abstract— Lithium preparations are considered the most 
reliable form of mood stabilizing medication for patients with 
Bipolar disorder. Nevertheless, lithium is a toxic element and 
its therapeutic range is extremely narrow, with levels of 0.6-
1.0mEq considered normal, whereas levels above 1.5mEq are 
toxic. Thus unfortunately, many patients reach toxic levels, 
which leads to unnecessary complications. It is believed that 
personal monitoring of blood lithium levels would benefit 
patients. Therefore, our aim is to develop a personal lithium 
blood level analyzer for patients with bipolar mood disorder, 
and we report here, our initial results using a colorimetric-
based method and testing drop-volumes of human plasma 
spiked with lithium. It was possible to validate results with 
standard flame photometry readings. Applying the Partial 
Least Squares (PLS) method on preprocessed spectra, 
therapeutic concentrations of lithium in a single drop can be 
predicted in a rapid manner, and furthermore, the calibration 
results were used to select the effective wavelengths which were 
employed as inputs in Multiple Linear Regression (MLR).  The 
simplified algorithms of this would prove useful when 
developing a personal lithium analyzer. Overall, both 
calibration methods gave high correlation and small error 
outputs with a R2= 0.99036 and RMSEC = 0.03778, and 
R2= 0.994148 and RMSEC= 0.0294404, for PLS and MLR 
methods, respectively. The results show that the 
spectrophotometric colorimetric determination of blood lithium 
levels can be extended beyond laboratory application and 
indicate the capability of this testing principle to be employed 
in a personal monitoring device. Future work will now focus on 
the technical development of a miniaturized system for 
measurement of lithium levels in blood with an acceptable level 
of accuracy and sensitivity.    
I. INTRODUCTION 
Bipolar disorder is a lifelong mood disorder characterized 
by episodes of hypomania/mania, almost always interspersed 
with episodes of depression [1, 2]. In the UK, the prevalence 
of bipolar disorder has been estimated at ~1% of the 
population [3], with a total cost of £342 million to the NHS at 
2009/2010 prices, and hospitalization accounting for £207 
million of that figure [1]. Various drugs are available as  part 
of long-term treatment of bipolar disorder, designed to 
prevent relapse or recurrence [4]. Of these, lithium is 
presented as first line as recommended by NICE guidance in 
September 2014 [4], and is known to be more effective in 
reducing the risk of suicide in patients with bipolar 
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disorder [5]. Nevertheless, lithium is potentially dangerous, 
and its therapeutic index is relatively narrow with normal 
levels being stated as 0.4-1.0mEq, whereas anything above 
1.5mEq is considered toxic. As a result, many patients often 
surpass this threshold, which in some cases, can lead to 
serious consequences such as renal failure, seizures, coma 
and even death [6].  
Moreover, toxicity can occur suddenly as a result of 
excessive intake or  due to accumulative high levels during 
ongoing chronic therapy [6]. At the moment, patients are 
obliged to attend regular blood tests, and lithium levels are 
analyzed using flame photometry which is by far, the most 
common method for this application. However, this method 
is mainly suitable for laboratory analysis, which although 
necessary, it is becoming apparent that more is required in 
monitoring lithium levels. This is because high rates of 
treatment nonadherence exist [7], and some reasons listed by 
NICE include the frequency of blood tests resulting in 
patients defaulting from treatment. Therefore, the availability 
of a personal monitor would be vastly beneficial to bipolar 
patients by improving their sense of involvement in the 
management of their illness, improving adherence with 
effective monitoring and facilitating early detection of 
shifting of lithium concentrations outside the therapeutic 
range.  
To meet this demand, we aim to develop a personal blood 
lithium analyzer for patients with bipolar disorder. As 
mentioned earlier, lithium concentrations are usually 
determined through flame photometry measurements of 
human serum/plasma. Alternative methods have been 
explored in the past [8]–[10] but unfortunately , a reliable 
device remains unavailable. We present here initial results of 
colorimetric determinations of lithium concentrations in 
drop-volumes of human plasma, based on a 
spectrophotometric analytical method that uses 1,4-
dihydroxyanthraquinone (Quinizarin) [11]. In addition, 
Partial Least Squares (PLS) and Multiple Linear Regression 
(MLR) are performed on data in order to investigate and 
compare the accuracy of concentration predictions using full-
range spectra and selected specific wavelengths.      
II. MATERIAL AND METHODS  
Ethics approval was granted by Senate Research Ethics 
committee at City University London prior to performing 
tests on samples of human plasma.  
A. Reagents and materials 
All experiments were conducted with analytical grade 
reagents, and aqueous solutions were prepared using distilled 
water.  
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A standard solution of 60mEq Lithium carbonate in saline 
was prepared, and subsequently, this was diluted further to 
make a set of solutions with the following concentrations: 18, 
24, 30, 36, 42, 48, 54 mEq. Additional reagents prepared 
were: 0.1 M of NaOH, 0.25 M of Na2CO3, 90 % (CH3)2SO 
and 1 mM of Quinizarin in (CH3)2SO.  
Frozen mixed pool blood plasma from healthy individuals 
was obtained from a reliable provider. Samples of human 
plasma that have been spiked with lithium were prepared by 
mixing 1 mL from each reagent of lithium carbonate 
prepared earlier i.e. 18, 24, 30, 36, 42, 48, 54 and 60mEq 
with 29 mL of blood plasma, thus giving 8 samples of 
30 mL, with lithium concentrations of 0.6-2.0 mEq.   
B. Testing procedure  
An amount of 500 µL from spiked samples of plasma 
were pipetted into a test tube, then were diluted with water to 
make up to 1 mL. For tests performed using a standard 1 mm 
quartz cell, a procedure similar to that described by Gracia et 
al [11] was followed where 100 µL from diluted plasma was 
mixed with 100 µL of 0.1 M NaOH, 10 µL of 0.25 M 
Na2CO3, 40 µL of water, 2.15 mL of 90 % (CH3)2SO and 
100 µL of 1mM of Quinizarin in (CH3)2SO.  
Tests performed using drop-volumes of plasma required 
slight modifications to the procedure described previously. 
Instead, the volumes of diluted plasma and Quinizarin were 
reduced to 50 µL. The same volumes were maintained for the 
remainder of reagents. Prior to testing, all samples were kept 
in a thermostatic bath at 25º for 30 mins.  
C. Instrumental setup  
The PerkinElmer Lambda 1050 dual beam 
spectrophotometer (PerkinElmer Corp, Waltham, MA) was 
used, with two different types of cells. The first was a set of 
standard 1 mm quartz cells, and the second was the Traycell 
(Helma GmbH & Co, Mulheim, Germany), which only 
requires 4-5 µL of the sample to be measured.  Absorbance 
measurements using standard quartz cells of 1 mm thickness 
were taken with a reagent blank prepared under identical 
conditions being placed in the reference compartment. When 
using the Traycell, the reagent blank was measured 
separately then subtracted from the remainder of spectra.  
The instrument was setup to acquire spectra between 450-
700 nm at increments of 1 nm, with a response time of 
0.2 secs and two running cycles for each sample. Slit width 
of the detector was fixed at 2 nm, and both reference and 
sample attenuators were kept at 100 %. Data pre-treatment, 
Partial Least Squares (PLS) and Multiple Linear Regression 
(MLR) analysis were performed using the Matlab® software 
(Mathworks Inc, Novi, MI), and the PLS-toolbox 
(Eigenvector Research Inc, Manson, WA) Matlab® add-on. 
The pre-processing methods which were applied to the 
spectra included weighted least squares baseline correction, 
and Savitsky-Golay algorithms for both smoothing and 
second derivatives.   
III. RESULTS AND DISCUSSIONS 
Fig. 1 shows the original absorbance  spectra and the 
second derivative spectra of therapeutic concentrations of 
lithium, recorded using a standard pair of 1 mm pathlength 
cells, where particularly in the latter, similar patterns are 
observed which showed expected variations in absorption 
minima between 601-607 nm regions, and which correlated 
with the amounts of lithium in the sample. Less significant 
but proportional changes with lithium concentrations were 
also observed in minima absorptions between 557-562 nm. 
Thus in both regions, spiked samples which contained the 
most amount of lithium expressed more intense absorptions 
and this decreased in accordance with lessening of lithium.  
Nevertheless, once this procedure was repeated using the 
Traycell, in order to explore the possibility of accurate 
determinations of lithium using only drop-volumes of blood, 
the resulting spectra shown in Fig. 2(a) were found. As can 
be seen, absorptions witnessed previously in Fig. 1 were 
significantly reduced, with a more complex relationship 
existing now between lithium levels and absorptions at the 
relevant bands. Hence, it was necessary to alter the ratios of 
NaOH, Quinizarin and spiked sample until reasonable 
absorptions were achieved. The resulting spectra of the 
modified testing procedure, described previously in the 
 
Figure 1. Raw spectra (top), and Second derivative spectra (bottom) of 
therapeutic concentrations of lithium in human plasma, tested using a 
colorimetric method with standard 1 mm quartz cells. 
  
methods section, are shown in Fig. 2(b), where once again, a 
somewhat linear relationship is evident between lithium 
concentrations of spiked samples and peak absorptions at the 
relevant bands. 
Given the improved spectral outputs, PLS analysis was 
carried out on the data acquired and shown in Fig. 2(b) to 
establish a rapid method for lithium determinations using 
chemometrics, The spectral region selected to build the PLS 
calibration of the measured set was between 480-690 nm, 
using pre-processed data and venetian blinds cross-
validation. The generated model could explain 81.80 % of 
spectral variations using two Latent Variables (LVs), each 
accounting for 57.53 % and 24.27 % of the total. In turn, this 
could explain 99.04 % of the variations in concentrations of 
lithium in spiked samples, as measured by flame photometry. 
The model produced a low calibration error and high 
correlation coefficient, as indicated by the root mean error of 
calibration (RMSEC) and R2 values shown in Table. 1.  
Moreover, the loadings plot of the PLS calibration is shown 
in Fig 3. This was used to determine the bands which 
contributed mostly to the calibration, and which would of 
significance to predicting lithium concentrations. Hence 
looking at the plot in Fig. 3, it can be seen that two ranges 
were mainly of significance to explaining the variations in 
spectral data, and these were around 560-570 and 605-
615 nm, which again, is in correspondence with the 
absorptions bands observed earlier in Fig. 2(b). Using this 
information, spectral band values around 560 and 605 nm, 
prior to averaging, were extracted in order to be used in a 
the linear regression calibration. A third region around 
660 nm was also included in the analysis. The linear 
regression analysis was carried out in order to establish a 
direct and simple combination of three selected wavelengths 
in relation to flame photometer readings, which in turn, 
would be used in developing the necessary algorithms in a 
miniaturized instrument that would employ a few selected 
wavelengths without the need of acquisition and analysis of 
full range spectra.  
Similar to PLS results, MLR analysis also yielded a 
calibration model of high correlation (R2) and low RMSEC. 
Table. 1 shows the values for these for both calibration and 
cross-validation processes. Therefore, lithium concentrations 
can be measured accurately using a few selected 
wavelengths, which in turn, can allow appropriate 
















Figure 2. Second derivative spectra of therapeutic concentrations of lithium 
in human plasma tested using Traycell; (top) prior to, and (bottom) after 
optimizing the testing procedure. 
Table 1. Calibration and cross-validation results of PLS and MLR 
analysis for determination of lithium levels in blood.   
 
 Calibration method 
 PLS  MLR  
RMSEC 0.0377837 0.0294404 
RMSECV 0.0559696 0.0689933 
Bias 2.22E-16 0 
CV Bias  0.0193917 0.00833188 
R
2
 Cal 0.99036 0.994148 
R
2
 CV 0.982965 0.968488 
 
Figure 3. Loadings points from PLS regression results based on two 
explanatory variables. 
  
of this process is apparent in Fig. 4, which shows a plot of 
the measured concentration of lithium against that predicted 
by linear regression.  
IV. CONCLUSIONS 
A colorimetric method that uses the chromogenic agent 
Quinizarin was employed and modified to allow 
determinations of lithium levels in drop-volumes of blood. 
The resulting spectra of the modified testing procedure 
showed spectral variations which could be related to lithium 
concentration in spiked samples of human plasma. 
Moreover, these were used to conduct PLS calibration, 
which yielded a model with high correlation coefficient and 
low root mean error. Based on this, it was also possible to 
reduce the number of required wavelengths and hence 
support future development of a miniaturized, multi-
wavelength system, by conducting linear regression on three 
selected wavelengths only. This too produced reliable 
calibration of the measured set. In conclusion, these results 
show that the colorimetric method can be modified to allow 
accurate and rapid determinations of lithium in drop-
volumes of blood of roughly 4-5 µL, and only using a few 
effective wavelengths to do this. Future work will now focus 
on improving the predication ability of the calibration by 
testing against more unknown samples, as well as building 
and evaluating the miniaturized system which would employ 
this measuring principle to provide readings of lithium levels 
in micro volumes of blood.     
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Figure 4. Predicted versus measured using only three wavelengths as 
variables.  
